vs

Side-by-side financial comparison of CITIZENS & NORTHERN CORP (CZNC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

CITIZENS & NORTHERN CORP is the larger business by last-quarter revenue ($36.9M vs $35.5M, roughly 1.0× RECURSION PHARMACEUTICALS, INC.). CITIZENS & NORTHERN CORP runs the higher net margin — 12.1% vs -304.2%, a 316.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 31.6%). CITIZENS & NORTHERN CORP produced more free cash flow last quarter ($30.1M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 19.7%).

Northern Trust Corporation is an American financial services company headquartered in Chicago, Illinois, that caters to corporations, institutional investors, and ultra high net worth individuals. Northern Trust is one of the largest banking institutions in the United States and one of the oldest banks in continuous operation. As of December 31, 2025, it had $1.8 trillion in assets under management and $14.9 trillion in assets under custody. Northern Trust Corporation is incorporated in Delaw...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

CZNC vs RXRX — Head-to-Head

Bigger by revenue
CZNC
CZNC
1.0× larger
CZNC
$36.9M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+650.2% gap
RXRX
681.7%
31.6%
CZNC
Higher net margin
CZNC
CZNC
316.4% more per $
CZNC
12.1%
-304.2%
RXRX
More free cash flow
CZNC
CZNC
$77.4M more FCF
CZNC
$30.1M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
19.7%
CZNC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CZNC
CZNC
RXRX
RXRX
Revenue
$36.9M
$35.5M
Net Profit
$4.5M
$-108.1M
Gross Margin
59.8%
Operating Margin
14.6%
-304.8%
Net Margin
12.1%
-304.2%
Revenue YoY
31.6%
681.7%
Net Profit YoY
-45.4%
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZNC
CZNC
RXRX
RXRX
Q4 25
$36.9M
$35.5M
Q3 25
$29.6M
$5.2M
Q2 25
$29.3M
$19.2M
Q1 25
$27.0M
$14.7M
Q4 24
$28.0M
$4.5M
Q3 24
$27.3M
$26.1M
Q2 24
$27.3M
$14.4M
Q1 24
$25.7M
$13.8M
Net Profit
CZNC
CZNC
RXRX
RXRX
Q4 25
$4.5M
$-108.1M
Q3 25
$6.6M
$-162.3M
Q2 25
$6.1M
$-171.9M
Q1 25
$6.3M
$-202.5M
Q4 24
$8.2M
$-178.9M
Q3 24
$6.4M
$-95.8M
Q2 24
$6.1M
$-97.5M
Q1 24
$5.3M
$-91.4M
Gross Margin
CZNC
CZNC
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
CZNC
CZNC
RXRX
RXRX
Q4 25
14.6%
-304.8%
Q3 25
27.1%
-3327.6%
Q2 25
25.7%
-916.8%
Q1 25
28.6%
-1297.9%
Q4 24
36.1%
-4042.4%
Q3 24
28.6%
-377.1%
Q2 24
27.4%
-697.4%
Q1 24
25.1%
-698.4%
Net Margin
CZNC
CZNC
RXRX
RXRX
Q4 25
12.1%
-304.2%
Q3 25
22.2%
-3135.3%
Q2 25
20.9%
-894.2%
Q1 25
23.3%
-1373.3%
Q4 24
29.2%
-3935.5%
Q3 24
23.3%
-367.5%
Q2 24
22.4%
-676.6%
Q1 24
20.6%
-662.4%
EPS (diluted)
CZNC
CZNC
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$0.42
$-0.36
Q2 25
$0.40
$-0.41
Q1 25
$0.41
$-0.50
Q4 24
$0.53
$-0.56
Q3 24
$0.41
$-0.34
Q2 24
$0.40
$-0.40
Q1 24
$0.35
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZNC
CZNC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$46.1M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$341.7M
$1.1B
Total Assets
$3.1B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZNC
CZNC
RXRX
RXRX
Q4 25
$46.1M
$743.3M
Q3 25
$123.1M
$659.8M
Q2 25
$99.6M
$525.1M
Q1 25
$114.7M
$500.5M
Q4 24
$126.2M
$594.4M
Q3 24
$184.2M
$427.6M
Q2 24
$100.4M
$474.3M
Q1 24
$46.4M
$296.3M
Total Debt
CZNC
CZNC
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
CZNC
CZNC
RXRX
RXRX
Q4 25
$341.7M
$1.1B
Q3 25
$294.0M
$1.0B
Q2 25
$286.4M
$919.1M
Q1 25
$281.8M
$933.9M
Q4 24
$275.3M
$1.0B
Q3 24
$277.3M
$524.6M
Q2 24
$263.2M
$584.4M
Q1 24
$261.7M
$401.2M
Total Assets
CZNC
CZNC
RXRX
RXRX
Q4 25
$3.1B
$1.5B
Q3 25
$2.7B
$1.4B
Q2 25
$2.6B
$1.3B
Q1 25
$2.6B
$1.3B
Q4 24
$2.6B
$1.4B
Q3 24
$2.7B
$726.5M
Q2 24
$2.6B
$775.9M
Q1 24
$2.5B
$557.8M
Debt / Equity
CZNC
CZNC
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZNC
CZNC
RXRX
RXRX
Operating Cash FlowLast quarter
$32.0M
$-46.1M
Free Cash FlowOCF − Capex
$30.1M
$-47.3M
FCF MarginFCF / Revenue
81.6%
-133.1%
Capex IntensityCapex / Revenue
5.2%
3.5%
Cash ConversionOCF / Net Profit
7.17×
TTM Free Cash FlowTrailing 4 quarters
$50.1M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZNC
CZNC
RXRX
RXRX
Q4 25
$32.0M
$-46.1M
Q3 25
$11.3M
$-117.4M
Q2 25
$8.5M
$-76.4M
Q1 25
$1.6M
$-132.0M
Q4 24
$33.0M
$-115.4M
Q3 24
$6.6M
$-59.2M
Q2 24
$8.6M
$-82.2M
Q1 24
$5.7M
$-102.3M
Free Cash Flow
CZNC
CZNC
RXRX
RXRX
Q4 25
$30.1M
$-47.3M
Q3 25
$10.9M
$-117.6M
Q2 25
$8.0M
$-79.6M
Q1 25
$1.0M
$-133.8M
Q4 24
$31.1M
$-116.7M
Q3 24
$6.4M
$-63.8M
Q2 24
$8.0M
$-83.4M
Q1 24
$5.0M
$-109.0M
FCF Margin
CZNC
CZNC
RXRX
RXRX
Q4 25
81.6%
-133.1%
Q3 25
36.9%
-2272.5%
Q2 25
27.4%
-413.9%
Q1 25
3.9%
-907.4%
Q4 24
111.1%
-2567.7%
Q3 24
23.6%
-244.6%
Q2 24
29.2%
-578.5%
Q1 24
19.4%
-789.9%
Capex Intensity
CZNC
CZNC
RXRX
RXRX
Q4 25
5.2%
3.5%
Q3 25
1.4%
4.7%
Q2 25
1.7%
16.4%
Q1 25
2.0%
12.4%
Q4 24
6.8%
28.6%
Q3 24
0.5%
17.5%
Q2 24
2.4%
8.2%
Q1 24
2.9%
48.2%
Cash Conversion
CZNC
CZNC
RXRX
RXRX
Q4 25
7.17×
Q3 25
1.73×
Q2 25
1.39×
Q1 25
0.25×
Q4 24
4.04×
Q3 24
1.04×
Q2 24
1.41×
Q1 24
1.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons